Clinical Trial

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Enrolling by Invitation 2026-08-08
notable Trial sites expanded: 3 -> 8 locations 2026-07-30
critical Recruitment opened 2026-04-15
notable Trial sites expanded: 0 -> 3 locations 2026-04-15
Trial Details
NCT Number NCT07459660
Lead Sponsor MapLight Therapeutics
Conditions Psychosis Associated With Alzheimer's Disease
Enrollment 210 participants
Start Date 2026-03-25
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-07